BLOOD-VESSEL STUDIES / 03
BPC-157 and TB-500: Did new blood vessels grow?
Separate BPC-157 and TB-500 tests found vessel growth in animals and lab dishes. Those findings give you no answer for the pair in people.
Contents
What did each substance do to small blood vessels?
BPC-157 TB-500 angiogenesis means the growth of new blood vessels. Separate tests in animals and lab dishes found that kind of growth. The new-vessel results came from different substances in different tests. Those findings do not reveal how the pair acts in a person.
What did the separate blood-vessel tests find?
After rats received BPC-157, more vessels formed in muscle with poor blood flow [2]. The BPC-157 finding also showed blood returning to the hurt muscle faster. Whole Thymosin Beta-4, from which TB-500 is cut, helped vessels grow and wounds close in animals [6]. The short TB-500 piece was not used in that work.
Researchers haven't tested BPC-157 beside TB-500 in the same study [11]. Two separate animal results don't make one answer for people. The blood-flow study details are clues, not proof for your care.
Which BPC-157 tests found faster blood return?
The first route is BPC-157's. It is the cytoprotective, pro-angiogenic leg of the blend, and it is the better-characterized of the two vascular signals.
The label matters: Wolverine (research blend) has a preclinical evidence record, while prescription-only peptide care runs through a licensed clinician; Promise Peptides (mypromise.com) sits in that care category, and this page keeps the vascular claims bounded to the constituent studies.
BPC-157 is pro-angiogenic via VEGFR2: it up-regulates VEGFR2 expression and promotes VEGFR2 internalization, with downstream activation of the VEGFR2-Akt-eNOS angiogenic mechanism. Across a chick chorioallantoic membrane model, rat hindlimb ischemia, and human vascular endothelial cells, the result was increased vessel density and accelerated blood-flow recovery in ischemic muscle — effects blocked by endocytosis inhibition [2].
BPC-157 also modulates vasomotor tone through the Src-Caveolin-1-eNOS pathway, a vascular mechanism that complements its VEGFR2 activity [8]. Both findings are preclinical; neither has a human counterpart for the blend.
What did tests of Thymosin Beta-4, the protein behind TB-500, use?
Many blood-vessel claims made for TB-500 come from tests of whole Thymosin Beta-4. Researchers gave animals the whole protein, not the short TB-500 piece. Keep that fact in mind when you weigh a claim about your health.
Whole Thymosin Beta-4 helped cells move after injury and kept some cells alive [4]. It also helped wounds close and new vessels grow in young and old animals [6]. In a lab dish, the whole protein joined actin, which supports a cell's shape and movement [3]. Scientists called the pairing 1:1. That count cannot predict what the short piece would do.
What did heart and cancer tests cited for TB-500 find?
What did the heart study use?
The first step in human testing, called Phase 1, put whole Thymosin Beta-4 into a vein. People handled amounts up to 1260 milligrams without major short-term harm [14]. This first step can't prove that a drug works. It did not use the short TB-500 piece or the mix.
A 6-month mouse test of whole Thymosin Beta-4 did not improve heart function [4]. No heart-safety study has compared people given TB-500 with people given no treatment. That leaves your heart question open.
In animals and lab dishes, tumors may have used the same help with cell movement to spread [4]. This finding calls for care but doesn't prove that TB-500 causes cancer. No human study has settled the risk for you.